Looking for a trusted supplier of Alectinib 150mg Capsules for advanced lung cancer treatment? Cordium Pharmaceuticals Pvt Ltd is a reliable pharmaceutical exporter from India delivering high-quality oncology medicines worldwide with fast, secure, and affordable shipping.
What is Alectinib 150mg?
Alectinib is a targeted anti-cancer medicine used primarily for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It works by blocking abnormal ALK proteins that help cancer cells grow and spread.
The medicine is widely prescribed for patients diagnosed with:
ALK-positive metastatic NSCLC
Advanced lung cancer
Post-surgery adjuvant treatment for ALK-positive lung cancer
Patients resistant or intolerant to crizotinib therapy
Recent FDA updates continue to support the effectiveness of alectinib in ALK-positive NSCLC treatment.
Product Description – Alectinib 150mg Capsules
Product Details
Attribute Description
Product Name Alectinib 150mg Capsules
Generic Name Alectinib
Drug Class ALK Inhibitor / Targeted Cancer Therapy
Strength 150mg
Dosage Form Oral Capsules
Indication ALK-positive Non-Small Cell Lung Cancer
Packaging Export Standard Packaging
Manufacturer & Exporter Cordium Pharmaceuticals Pvt Ltd
Country of Origin India
How Alectinib Works
Alectinib is a powerful ALK inhibitor designed to stop the growth and spread of cancer cells in patients with ALK gene mutations. It helps slow disease progression and improves progression-free survival in lung cancer patients.
Key Benefits of Alectinib 150mg Capsules
Targeted therapy for ALK-positive lung cancer
Helps control tumor growth
Effective for metastatic NSCLC
May reduce risk of recurrence after surgery
Oral capsule form for convenient administration
Globally recognized oncology treatment option
Recommended Dosage
The commonly recommended dosage is 600mg twice daily with food, or as prescribed by an oncologist. Dosage adjustments may be required based on patient condition and side effects.
Possible Side Effects
Patients may experience some side effects, including:
Fatigue
Constipation
Muscle pain
Swelling
Liver function abnormalities
Rash
Cough
Always use under medical supervision.
Why Choose Cordium Pharmaceuticals Pvt Ltd?
As a trusted pharmaceutical exporter in India, Cordium Pharmaceuticals Pvt Ltd is committed to supplying genuine oncology medicines worldwide.
Our Advantages
Trusted global pharmaceutical exporter
Competitive pricing on oncology medicines
Fast international delivery
Reliable export documentation support
Secure packaging standards
Bulk and retail order support
Responsive customer assistance
Worldwide shipping network
Countries We Export To
We offer affordable and reliable delivery of Alectinib 150mg Capsules to:
United States
Germany
United Kingdom
Netherlands
South Africa
United Arab Emirates
Brazil
We ensure safe, affordable, and timely medicine delivery worldwide.
Latest Global Demand for Alectinib
Alectinib continues to gain worldwide attention as a leading targeted therapy for ALK-positive lung cancer treatment. New clinical evidence and FDA approvals in 2024 strengthened its position in early-stage and metastatic NSCLC therapy.
Order & Enquiry
For wholesale, export, hospital supply, or patient assistance enquiries:
WhatsApp
📞 +91-9405117673
Email
📧 info@cordiumpharma.com
Official Website
www.cordiumpharma.com
What is Alectinib 150mg?
Alectinib is a targeted anti-cancer medicine used primarily for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It works by blocking abnormal ALK proteins that help cancer cells grow and spread.
The medicine is widely prescribed for patients diagnosed with:
ALK-positive metastatic NSCLC
Advanced lung cancer
Post-surgery adjuvant treatment for ALK-positive lung cancer
Patients resistant or intolerant to crizotinib therapy
Recent FDA updates continue to support the effectiveness of alectinib in ALK-positive NSCLC treatment.
Product Description – Alectinib 150mg Capsules
Product Details
Attribute Description
Product Name Alectinib 150mg Capsules
Generic Name Alectinib
Drug Class ALK Inhibitor / Targeted Cancer Therapy
Strength 150mg
Dosage Form Oral Capsules
Indication ALK-positive Non-Small Cell Lung Cancer
Packaging Export Standard Packaging
Manufacturer & Exporter Cordium Pharmaceuticals Pvt Ltd
Country of Origin India
How Alectinib Works
Alectinib is a powerful ALK inhibitor designed to stop the growth and spread of cancer cells in patients with ALK gene mutations. It helps slow disease progression and improves progression-free survival in lung cancer patients.
Key Benefits of Alectinib 150mg Capsules
Targeted therapy for ALK-positive lung cancer
Helps control tumor growth
Effective for metastatic NSCLC
May reduce risk of recurrence after surgery
Oral capsule form for convenient administration
Globally recognized oncology treatment option
Recommended Dosage
The commonly recommended dosage is 600mg twice daily with food, or as prescribed by an oncologist. Dosage adjustments may be required based on patient condition and side effects.
Possible Side Effects
Patients may experience some side effects, including:
Fatigue
Constipation
Muscle pain
Swelling
Liver function abnormalities
Rash
Cough
Always use under medical supervision.
Why Choose Cordium Pharmaceuticals Pvt Ltd?
As a trusted pharmaceutical exporter in India, Cordium Pharmaceuticals Pvt Ltd is committed to supplying genuine oncology medicines worldwide.
Our Advantages
Trusted global pharmaceutical exporter
Competitive pricing on oncology medicines
Fast international delivery
Reliable export documentation support
Secure packaging standards
Bulk and retail order support
Responsive customer assistance
Worldwide shipping network
Countries We Export To
We offer affordable and reliable delivery of Alectinib 150mg Capsules to:
United States
Germany
United Kingdom
Netherlands
South Africa
United Arab Emirates
Brazil
We ensure safe, affordable, and timely medicine delivery worldwide.
Latest Global Demand for Alectinib
Alectinib continues to gain worldwide attention as a leading targeted therapy for ALK-positive lung cancer treatment. New clinical evidence and FDA approvals in 2024 strengthened its position in early-stage and metastatic NSCLC therapy.
Order & Enquiry
For wholesale, export, hospital supply, or patient assistance enquiries:
📞 +91-9405117673
📧 info@cordiumpharma.com
Official Website
www.cordiumpharma.com
Keywords
